Exosomes Common Link in Cancer Drug Development
ACCESSWIRE - 37 mins ago
Whitefish, MT / May 15, 2014 / The cancer drug business is ablaze lately as pharmaceutical companies of all sizes are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are being held in high regard as the next generation of cancer therapies as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465 for patients with advanced melanoma who did not respond to Bristol-Myers Squibb's (NYSE: BMY) Yervoy. Roche is making headlines not just with MK-3465, releasing data ahead of the May 30 start of this year's American Society of Clinical Oncology (ASCO) meeting, showing that its immune therapy drug MPDL3280A shrunk tumors in 10 of 20 bladder cancer patients. Pfizer (NYSE: PFE) is looking to consolidate some of its developmental pipeline through potentially the biggest biotech acquisition in history, offering more than $100 billion to buy AstraZeneca (NYSE: AZN). AstraZeneca's MedImmune unit is partnered with Pfizer, working on development of an anti-CTLA-4 combination therapy. MedImmune expanded its pipeline this week by inking a pact with Incyte (NASDAQ: INCY) to couple its MEDI4736 with Incyte's INCB24360 in a PD-L1-targeting regimen.
Most active New York Stock Exchange-traded stocks
AP - 1 hr 23 mins ago
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - 1 hr 23 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:
American College of Physicians, CECity, and Pfizer collaborate to increase adult immunization rates
PR Newswire - Thu May 15, 10:27AM CDT
The American College of Physicians (ACP), CECity, and Pfizer Inc. (NYSE
Early Glance: Pharmaceuticals companies
AP - Thu May 15, 9:34AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:
Global PVA (Polyvinyl Alcohol) Drugs Market 2014-2018 with Actavis plc, Novo Nordisk A/S, Pfizer Inc. & Shionogi & Co. Ltd. Dominating
M2 - Thu May 15, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nd3bjw/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. Over the years, there has been a gradual increase in awareness about PVA. The acceptability of PVA drugs is expected to rise during the forecast period because of increasing public awareness about PVA and the need for treatment. This is expected to result in increasing drug penetration. The growth witnessed during the past was primarily because of the growing awareness among patients and physicians, which resulted in increased diagnosis and treatment rates. In the recent past, there have been several awareness and educational programs specifically targeting patients with PVA. For instance, Novo Nordisk, one of the prominent players of this market introduced the formation of GLAM to ignite the conversation on vaginal health in 2013. GLAM is basically an alliance that encourages women to discuss issues about the menopause and seek help. Thus, the increasing awareness and resultant higher treatment seeking rates for PVA are expected to contribute to the growth of the market during the forecast period. According to the report, the Global PVA Drugs market has substantial unmet needs. Currently, the market is not well served with the existing product options; therefore, there exists a significant opportunity for new vendors to capitalize on the market. The market has significant unmet needs in terms of low diagnosis rates, low levels of treatment seeking behavior among menopausal women, and safety concerns associated with ERT. Efficient and safe treatment options to meet the current demand are in the pipeline. Hence, there is huge potential for new entrants to grow by addressing the high unmet need of the market. Further, the report states that the patent expiries of major approved drugs will affect the market adversely and will slow down its growth during the forecast period. The shift toward lower priced drugs will lead to a drop in the market valuations for that drug, reducing the overall market value. The introduction of these low-cost drugs is likely to increase the competition in the market, thereby eventually reducing the price of key drugs. Key Vendors - Actavis plc - Novo Nordisk A/S - Pfizer Inc. - Shionogi & Co. Ltd. Other Prominent Vendors - ANI Pharmaceuticals Inc. - Bionovo Inc. - EndoCeutics Inc. - QuatRx Pharmaceutical Co. - PeP-Tonic Medical AB - Teva Pharmaceutical Industries Ltd. - Therapeutics MD Inc. - Upsher-Smith Laboratories Inc. Market Drivers/Challenges/Trends - Significant Unmet Need. - Increasing Number of Patent Expirations. - Increase in Awareness of PVA. For more information visit http://www.researchandmarkets.com/research/nd..._pva_drugs
GlycoMimetics Announces Presentation of Rivipansel Data in Pediatric Patients at American Society of Pediatric Hematology Oncology 27th Annual Meeting
Business Wire - Thu May 15, 8:03AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that data from a Phase 2 clinical trial of its lead drug candidate rivipansel (GMI-1070) in pediatric patients has been presented at the American Society of Pediatric Hematology Oncology (ASPHO) 27th Annual Meeting. As part of the symposium entitled, "Sickle Cell Disease: Saving the Brain and Treating the Pain," Timothy McCavit, M.D., M.S., Assistant Professor of Pediatric Hematology-Oncology at UT Southwestern Medical Center, highlighted the results observed in a randomized, multi-center, double-blind, adaptive Phase 2 study of rivipansel in pediatric sickle cell disease patients with vaso-occlusive crisis (VOC). The ASPHO Meeting is taking place May 14 through May 17 at the Palmer House Hilton in Chicago.
Why Pfizer's Huge Offer for AstraZeneca Actually Makes Sense
Bob Ciura, The Motley Fool - Motley Fool - Thu May 15, 6:00AM CDT
On the surface, offering $106 billion to take over a rival seems like nothing short of desperation. That's exactly what pharmaceutical giant Pfizer is doing, though, trying to acquire European competitor AstraZeneca . Pfizer has been through...
AstraZeneca sees deal hurdles
at Investor's Business Daily - Wed May 14, 5:40PM CDT
U.K. drugmaker AstraZeneca's (AZN) CEO, Pascal Soriot, on Wed. said he's open to talks with Pfizer (PFE) about a possible merger, but only if the price is right and certain risks are fully assessed, reports said. Soriot told Reuters he has concerns...
Final Glance: Pharmaceuticals companies
AP - Wed May 14, 5:13PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Exosomes Part and Parcel of Celldex, Pfizer, Incyte and More Cancer Targets
ACCESSWIRE - Wed May 14, 2:50PM CDT
Whitefish, MT / May 14, 2014 / Pharmaceutical companies big and small are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are receiving the praise of analysts as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465. Shares of Celldex Therapeutics (NASDAQ: CLDX) are chugging ahead by 25 percent on Wednesday after striking a deal with Bristol-Myers Squibb (NYSE: BMY) to collaborate on the clinical development of BMY's PD-1 investigational drug nivolumab in combination with Celldex's CD27-targeting drug candidate varlilumab.
Dow Today: Pfizer (PFE) Higher
at The Street - Wed May 14, 12:00PM CDT
The Dow component leading the way higher looks to be Pfizer (NYSE: PFE ), which is sporting a two-cent gain to $29.22.
Health Care Sector Equities Technical Analysis -- Research on CombiMatrix, Quintiles Transnational Holdings, Pfizer, and GW Pharma
PR Newswire - Wed May 14, 10:26AM CDT
The trading session on Tuesday, May 13, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,715.44, up 0.12% and the NASDAQ Composite closed at 4,130.17, down 0.33%. The S&P 500 finished the day 0.04% higher at 1,897.45. During the trading session, six out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.16% higher at 676.34, and the index has gained 0.84% in the previous three months. Investor-Edge has initiated coverage on the following equities: CombiMatrix Corp. (NASDAQ: CBMX), Quintiles Transnational Holdings Inc. (NYSE: Q), Pfizer Inc. (NYSE: PFE) and GW Pharmaceuticals PLC (NASDAQ: GWPH). Free technical research on CBMX, Q, PFE and GWPH can be downloaded upon signing up at:
Fitch Assigns an 'A+' Rating to Pfizer's Notes Offering
Business Wire - Wed May 14, 9:35AM CDT
Fitch Ratings has assigned an 'A+' rating to Pfizer Inc.'s (Pfizer's) $4.5 billion notes offering. Fitch expects Pfizer to use the net proceeds for general corporate purposes, including pre-funding the repayment at maturity of the EUR900 million outstanding of its 4.75% notes due December 2014 and pre-funding a portion of its outstanding 5.35% notes due March 2015. The rating action does not incorporate any effect from Pfizer's potential acquisition of AstraZeneca. The Rating Outlook is Stable. A full list of Pfizer's ratings is provided at the end of this release.
Research and Markets: Global Meningococcal Vaccines Market 2013 - 2019 - Polysaccharide, Conjugate, and Combination Vaccines, along with Pipeline Analysis
Business Wire - Wed May 14, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ft7dxb/meningococcal) has announced the addition of the "Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering.
Rep. Delaney Hopes Pfizer Anger Will Fuel Infrastructure Bill (Correction)
at The Street - Wed May 14, 9:31AM CDT
Anger over tax-driven megadeals has been reignited by Pfizer's proposed acquisition of AstraZeneca and Rep. John Delaney is hoping to harness that outrage to help build momentum for his trademark infrastructure legislation.
Athersys Reports Wider-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 9:04AM CDT
Athersys, Inc.'s (ATHX) first quarter 2014 net loss of 15 cents per share was wider than the Zacks Consensus Estimate of a loss of 9 cents.
Next Support Level for Pfizer (PFE) is $28.93
Comtex SmarTrend(R) - Wed May 14, 9:00AM CDT
Pfizer (NYSE
Global Meningococcal Vaccines Market 2013 - 2019 - Polysaccharide, Conjugate, and Combination Vaccines, along with Pipeline Analysis
M2 - Wed May 14, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bwh98b/meningococcal) has announced the addition of the "Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The key players contributing to the global meningococcal vaccines market include Sanofi SA, Novartis AG, GSK plc, Pfizer, Inc., Nuron Biotech, JN International Medical Corporation, Serum Institute of India Ltd., Baxter International and Biomed Pvt. Ltd. The global meningococcal vaccines market is segmented broadly into polysaccharide, conjugate and combination vaccines. These vaccine types are further segmented into different brands available in the market. Polysaccharide vaccines is the oldest type available in market since last three decades. However, the presence and widespread use of conjugate vaccines has drastically reduced the incidences of bacterial meningitis due to the prolonged immunity achieved against the disease-causing serogroups, unlike polysaccharide vaccines which provide immunity for a very short period. Combination vaccines against invasive meningococci in combination with other organisms such as pneumococcal and Haemophilus influenzae type B are considered as new weapons to fight against two bacterial infections. This has shown to reduce the number of injections needed to be administered when compared to their individual doses. Hence, combination vaccines are likely to have high growth in forthcoming years. The notable pipeline vaccines against meningococcal disease include Bexsero by Novartis, MnB rLP2806 by Pfizer and NmVac4-DT by JN International Medical Corporation. Novartis in January 2013, received marketing authorization for Bexsero as the only vaccine against serogroup B, across the European Union, Canada and Australia, and has been currently filed for U.S. FDA licensure. The rLP2806 vaccine, is currently in phase III clinical trials and has been granted Breakthrough Therapy Status by the U.S. FDA in 2014. NmVac4 DT, on the other hand, has been developed against the broad range of (quadrivalent) serogroups A, C, Y and W-135. Moreover, its manufacturer of the vaccine JN International Medical Corporation claims the vaccine to be animal component free, which is expected to be the major driver for its demand post market launch. Major growth drivers for the global meningococcal vaccines market include favourable public-private partnerships to support development of vaccines at low cost, and the medical emergency status of the disease. Increase in the demand for vaccines and number of people getting immunized has been majorly contributed to the education and awareness campaigns conducted by manufacturers as well as non-profit organizations in the developed economies. Government intervention such as approval of legislations to mandate immunization programs for school children up to a certain age, and stringent regulations for Hajj pilgrims and sub-Saharan travellers also contribute positively to this market due to increased demand for these vaccines from the non-profit organizations. The global meningococcal vaccines market is segmented as follow: Companies Mentioned - Baxter International, Inc. - Biomed Pvt. Ltd. - GlaxoSmithKline plc - JN-International Medical Corporation - Novartis International AG - Nuron Biotech, Inc. - Pfizer, Inc. - Sanofi SA - Serum Institute of India Ltd. Polysaccharide Vaccines, by Brand - Menomune - Mencevax - NmVac4 - Others -- Quadri Meningo -- Bi Meningo Conjugate Vaccines, by Brand - Menactra - Menveo - NeisVac-C - Nimenrix - Meningitec - Menjugate - MenAfriVac Combination Vaccines, by Brand - MenHibrix - Menitorix Pipeline Vaccines, by Brand - Bexsero - MnB rLP2806 - NmVac4-DT For more information visit http://www.researchandmarkets.com/research/bw...ingococcal